COMMUNIQUÉS West-GlobeNewswire

Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
11/02/2026
Melbourne, Australia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Two US-based sites have completed trial initiation activities for the AMPLICITY trial in pancreatic cancer These sites join the two Australian sites [...]
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET
11/02/2026
REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]
DIL Walk Foundation Takes National and Global Leadership Role in Advancing Precision Health and Healthspan
11/02/2026
CALGARY, Alberta, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The DIL Walk Foundation is strengthening its leadership role in advancing precision health, longevity research, and healthspan-focused care, positioning Canada as an [...]
iMDx Announces $26.0 Million Registered Direct Offering
11/02/2026
NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has entered into definitive agreements with certain [...]
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
11/02/2026
NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
HNL Lab Medicine Opens New Patient Service Center at The Marketplace at Steamtown
11/02/2026
SCRANTON, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine is expanding access to convenient, high-quality laboratory services with the opening of a new Patient Service Center at The Marketplace at Steamtown, [...]
SRx Health Solutions Redeems Series A Preferred Stock and Cancels Approximately 125,000,000 Shares of Common Stock, Improving Balance Sheet Flexibility for Investment in M&A or Return of Capital to Shareholders
11/02/2026
NORTH PALM BEACH, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced that it has redeemed 17,500 shares of its Series A Preferred Stock pursuant to [...]
Genvor’s AGM182 Antifungal Peptide Technology Validated in Peer-Reviewed Publication in PhytoFrontiers™
11/02/2026
Greenhouse trial results published jointly with USDA-ARS demonstrate 76-98% reduction in aflatoxin contamination in transgenic corn expressing the BioCypher-designed peptide AGM182 Woodland, CA, Feb. 11, 2026 (GLOBE [...]
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
11/02/2026
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: [...]
Clairity Founder and CEO, Dr. Connie Lehman, Named to TIME’s 2026 TIME100 Health List
11/02/2026
A Global Leader in Breast Imaging and AI, Dr. Lehman is Advancing AI-Driven Risk Assessment to Identify Women at Elevated Risk Years Before Diagnosis TIME’s Annual List Recognizes 100 of the World’s Most Influential [...]
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
11/02/2026
The Company is in Advanced Stage s of Commercial U.S. Partner ship Discussions for D-PLEX₁₀₀ Positive FDA Pre-NDA Feedback Supports Rolling NDA Review ; Submission Expected to Begin by the E nd of the First Quarter of [...]
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
11/02/2026
Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026 If approved, Ameluz ® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma [...]
VIVUS Advances Patient Access with New Copay Assistance Program for PANCREAZE®
11/02/2026
— Commercially-insured patients can pay as little as $0 on their copay and up to $2,000 per fill for their PANCREAZE ® prescription CAMPBELL, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical [...]
Psyence BioMed Announces Settlement of Shareholder Litigation
11/02/2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (" Psyence BioMed " or the " Company ") today announced that it has entered into a settlement agreement to resolve a direct shareholder [...]
MBX Biosciences to Participate in Upcoming Investor Conferences
11/02/2026
CARMEL, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide [...]
24/7 Market News - Not Magic, Just Science: Kraig Labs’ Transgenic Silkworms Make History at Scale
11/02/2026
Kraig Labs Cracks the Spider Silk Code DENVER, Feb. 11, 2026 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that [...]
AIM ImmunoTech Announces Commencement of Rights Offering
11/02/2026
OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead [...]
Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board
11/02/2026
Dr. Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation, effective April 1, 2026 Industry expert [...]
HepaRegeniX Completes Phase Ib Study of HRX-215 to Enhance Liver Regeneration in Patients Undergoing Minor Liver Resection
11/02/2026
Tuebingen, Germany, February 11, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib [...]

Pages